Lifecore Biomedical to Participate at DCAT Week 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.
Details regarding Lifecore’s participation are as follows:
- DCAT Week 2026
Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs.
Conference Dates: March 23-26, 2026
Location: New York, NY
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Are European ETFs Facing Risks Amid the Iran Crisis?
LPL Financial Promotes Kirby Horan-Adams and Joe Lanser to Managing Director

Blaize to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026


